DNA damage and repair in translational oncology: An overview

Clinical Cancer Research

Volumn 16, Issue 18, 2010, Pages 4511-4516

  Reed, Eddie ^a  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; DOUBLE STRANDED DNA;

ADVANCED CANCER; BREAST CANCER; CANCER THERAPY; DNA DAMAGE; DNA REPAIR; EXCISION REPAIR; PRIORITY JOURNAL; REVIEW; X IRRADIATION; XERODERMA PIGMENTOSUM;

DNA DAMAGE; DNA REPAIR; EVIDENCE-BASED MEDICINE; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; SIGNAL TRANSDUCTION; TRANSLATIONAL RESEARCH; TUMOR MARKERS, BIOLOGICAL;

EID: 77956675859     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0528     Document Type: Review

References (40)

1. Reed E. Cisplatin and platinum analogs. In: DeVita VT, Rosenberg SA, Lawrence TS, editors. Cancer principles and practice of oncology. 8th ed. Philadelphia: Lippincott, Williams, and Wilkins; 2008, p. 419-26.
2. Reed E. Cisplatin, carboplatin, oxaliplatin and analogs. In: Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy: principles and practice. 5th ed. Philadelphia: Lippincott, Williams & Wilkins. In press 2010.
3. Annunziata CM, O'Shaughnessy J. Poly(ADP-Ribose) Polymerase as a novel therapeutic target in cancer. Clin Cancer Res 2010;16:4517-26.
4. Plummer R. Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target. Clin Cancer Res 2010;16:4527-31.
5. Redon CE, Nakamura AJ, Zhang Y, et al. Histone ãH2AX and Poly (ADP ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res 2010;16:4532-42.
6. Rossetto D, Truman AW, Kron SJ, Côté J. Epigenetic modification in double-strand break DNA damage signaling and repair. Clin Cancer Res 2010;16:4543-52.
7. Chan N, Bristow RG. "Contextual" synthetic lethality/loss of heterozygosity: tumor hypoxia and modification of DNA repair. Clin Cancer Res 2010;16:4553-60.
8. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
9. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010;376:235-44. Epub 2010 Jul 6.
10. O'Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. J Clin Oncol 2009;27:3.
11. Hoeijmakers JHJ. DNA damage, aging, and cancer. N Engl J Med 2009;361:1475-85.
12. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009;461:1071-8.
13. Cleaver JE, Lam ET, Revet I. Disorders of nucleotide excision repair: the genetic and molecular basis of heterogeneity. Nat Rev Genet 2009;10:756-68.
14. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-91. (Pubitemid 44343542)
15. Reed E. ERCCI measurements in clinical oncology. N Engl J Med 2006;355:1054-5.
16. Westerveld A, Hoeijmakers JH, van Duin M, et al. Molecular cloning of a human DNA repair gene. Nature 1984;310:425-9. (Pubitemid 14051113)
17. Ahmad A, Robinson AR, Duensing A, et al. ERCC1-XPF endonuclease facilitates DNA double-strand break repair. Mol Cell Biol 2008;28:5082-92.
18. Al-Minawi AZ, Lee YF, Hakansson D, et al. The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links. Nucleic Acids Res 2009;37:6400-13.
19. Altaha R, Liang X, Yu JJ, Reed E. ERCC-1 gene expression and platinum resistance. Int J Mol Med 2004;14:959-70.
20. Lee KB, Parker RJ, Bohr VA, Cornelison TC, Reed E. Cisplatin sensitivity/resistance in UV-repair deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis 1993;14:2177-80. (Pubitemid 23311452)
21. Yu JJ, Mu C, Lee KB, et al. A nucleotide polymorphism in ERCC1 gene in human ovarian cancer cell lines and tumor tissues. Mutat Res 1997;382:13-20. (Pubitemid 28376643)
22. Viguier J, Bioge V, Miquel C, et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2005;11:6212-7.
23. Reed E. ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res 2005;11:6100-2. (Pubitemid 41262934)
24. Vilmar A, Sorensen JB. Excison repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of the current literature. Lung Cancer 2009;64:131-9.
25. Olaussen KA, Mountzios G, Soria JC. ERCC1 as a risk stratifier in platinum-based chemotherapy for non-small cell lung cancer. Curr Opin Pulm Med 2007;13:284-9. (Pubitemid 46847293)
26. Gao R, Price DK, Dahut WL, Steinberg SM, Reed E, Figg WD. Genetic polymorphisms in XRCC1 associated with clinical response to radiation therapy in prostate cancer. Cancer Biol Ther 2010;10. Epub 2010 Jul 26.
27. Yoon SM, Hong Y-C, Park JH, et al. The polymorphism and haplotypes of XRCC1 and survival of non-small cell lung cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2005;63:885-91.
28. Moullan N, Cox DG, Angele S, Romestaing P, Gerard J-P, Hall J. Polymorphisms in the DNA repair gene XRCC1, breast cancer risk, and response to radiotherapy. Cancer Epidemiol Biomarkers Prev 2003;12:1168-74. (Pubitemid 37499439)
29. Li Q, Gardner K, Zhang L, Tsang B, Bostick-Bruton F, Reed E. Cisplatin induction of ERCC1 mRNA expression in A2780/CP70 human ovarian cancer cells. J Biol Chem 1998;273:23419-25. (Pubitemid 28417531)
30. Li Q, Tsang B, Gardner K, Bostick-Bruton F, Reed E. Phorbol ester exposure activates an AP-1 associated increase in ERCC1 mRNA expression in human ovarian cancer cells. Cell Mol Life Sci 1999;55:456-66. (Pubitemid 29178884)
31. Li Q, Ding L, Yu JJ, et al. Cisplatin and phorbol ester independently induce ERCC1 protein in human ovarian tumor cells. Int J Oncol 1998;13:987-92. (Pubitemid 28506069)
32. Li Q, Bostick-Bruton F, Reed E. Modulation of ERCC-1 mRNA expression by pharmacological agents in human ovarian cancer cells. Biochem Pharmacol 1999;57:347-53.
33. Li QQ, Ding L, Reed E. Proteasome inhibition suppresses cisplatin-dependent ERCC-1 mRNA expression in human ovarian tumor cells. Res Commun Mol Pathol Pharmacol 2000;107:387-96. (Pubitemid 32906183)
34. Bonovich M, Olive M, Reed E, O'Connell B, Vinson C. Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines. Cancer Gene Ther 2002;9:62-70. (Pubitemid 34052855)
35. Yan QW, Reed E, Zhong XS, Thornton K, Guo Y, Yu JJ. MZF1 possesses a repressively regulatory function in ERCC1 expression. Biochem Pharmacol 2006;71:761-71. (Pubitemid 43208832)
36. Kudo K, Gavin E, Das S, et al. Inhibition of Hedgehog results in altered regulation of c-jun and of ERCC1, in cisplatin-resistant A2780-70 human ovarian cancer cells. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; 2010, p. Abstract nr LB-281.
37. Reed E, Kudo K, Shevede-Samant L, et al. Factors that influence the regulation of ERCC1 in drug resistant cells. Proceedings of the Translational Cancer Medicine 2010 (Europe) Meeting of the American Association for Cancer Research; 2010 Mar 21-24; Amsterdam. Philadelphia (PA): AACR; 2010, p. Abstract nr 58.
38. Bicher A, Ault K, Kimmelman A, Gershenson D, Reed E, Liang B. Loss of heterozygosity in human ovarian cancer on chromosome 19q. Gynecol Oncol 1997;66:36-40. (Pubitemid 27329305)
39. Zhong X, Thornton K, Reed E. Computer based analyses of the 5′-flanking regions of selected genes involved in the nucleotide excision repair excision complex. Int J Oncol 2000;17:375-80.
40. Munshi A, Tanaka T, Hobbs M, Tucker S, Richon V, Meyn R. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther 2006;5:1967-74. (Pubitemid 44336568)